CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Lenalidomide +2 moredrug
Likely dose
Lenalidomide 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00890552
NCT00890552N/ACompleted
CompareCT.gov

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Stanford University·interventional·Posted Apr 30, 2009·Updated Mar 22, 2017

In Brief

A clinical study evaluating Lenalidomide, Melphalan, and 1 other intervention for Leukemia and Amyloidosis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Amyloidosis
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 30, 2009
Enrollment StartApr 1, 2009
Primary CompletionAug 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.2 years ago

Interventions

Lenalidomidedrug

Lenalidomide is a a derivative of thalidomide. Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle.

Melphalandrug

Melphalan is a phenylalanine derivative of mechlorethamine. Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle

Dexamethasonedrug

Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication. Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle